3 active not recruiting, 3 recruiting. 6 Phase 3, 3 Phase 2.
By phase and status
Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib
Trials (filtered) newest first · largest first
All 6 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | 30 | 2025-11-30 | 2025-11-24 |
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Ipatasertib, Tiragolumab, Atezolizumab - Cancer | Phase 3 | Recruiting | 200 | 2023-06-01 | 2026-11-06 |
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | 825 | 2023-03-01 | 2026-07-01 |
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Alectinib, Entrectinib, Durvalumab - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | 68 | 2022-11-01 | 2026-11-02 |
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Entrectinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | 217 | 2021-09-30 | 2026-08-13 |
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Alectinib, Atezolizumab, Pemetrexed - Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | 1000 | 2017-09-22 | 2026-09-03 |
Conditions studied
Carcinoma, Non-Small-Cell Lung (3) · Neoplasms (3) · Hematologic Neoplasms (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Brain Neoplasms (1) · Glioma (1) · Melanoma (1)
Sponsors
Hoffmann-La Roche (4) · Cancer Research UK (2)
Countries
China (4) · France (4) · Mexico (4) · Thailand (4) · United Kingdom (4) · Belgium (3) · Brazil (3) · Germany (3) · Italy (3) · Japan (3) · Poland (3) · South Korea (3) · Taiwan (3) · Australia (2) · Canada (2)
Top investigators
Matthew Krebs, Dr (2)
Results publications
PMID 35995953, PMID 38190582, PMID 38898120, PMID 40525978
NIH funding
2023 (3), 2017 (1), 2019 (1)